DNA methylation based biomarkers for early detection of cancer

DNA methylation based biomarkers
for early detection of cancer

Montreal EpiTerapia anticipates exponential growth in DNA methylation/next generation sequencing based assays in the coming years. Our immediate focus is on tests for the common disease that affects large segments of the population, help prevention and early treatment of disease and effects lives and well-being of a large number of people. 

Montreal EpiTerapia leverages on three decades of pioneering research in epigenetics and DNA methylation by its founding director.

DNA methylation is a chemical mark on our DNA that is programmed during development but changes when cancer and many other diseases develop. Measuring these changes in DNA methylation could detect the development of diseases such as cancer early.

The company believes that the emerging science of DNA methylation offers untapped potential for new diagnostics in a wide spectrum of conditions that will affect lives of millions globally. We believe that early introduction of these novel diagnostics into emerging markets will have a singular impact on people of these countries and quality of their health care. 

Montreal EpiTerapia is interested in building licensing partnerships in this area. Please contact us for further information.